Literature DB >> 20594025

Repeat decompression surgery for recurrent spinal metastases.

Ilya Laufer1, Andrew Hanover, Eric Lis, Yoshiya Yamada, Mark Bilsky.   

Abstract

OBJECT In this paper, the authors' goal was to determine the outcome of reoperation for recurrent epidural spinal cord compression in patients with metastatic spine disease. METHODS A retrospective chart review was conducted of all patients who underwent spine surgery at the Memorial Sloan-Kettering Cancer Center between 1996 and 2007. Thirty-nine patients who underwent reoperation of the spine at the level previously treated with surgery were identified. Only patients whose reoperation was performed because of tumor recurrence leading to high-grade epidural spinal cord compression or recurrence with no further radiation options were included in the study. Patients who underwent reoperations exclusively for instrumentation failure were excluded. All patients underwent additional decompression via a posterolateral approach without removal of the spinal instrumentation. RESULTS Patients underwent 1-4 reoperations at the same level. A median survival time of 12.4 months was noted after the first reoperation, and a median survival time of 9.1 months was noted after the last reoperation. At last follow-up 22 (65%) of 34 patients were ambulatory at the time of last follow-up or death, and the median time between loss-of-ambulation and death was 1 month. Functional status was maintained or improved by one Eastern Cooperative Oncology Group grade in 97% of patients. A major surgical complication rate of 5% was noted. CONCLUSIONS Reoperation represents a viable option in patients with high-grade epidural spinal cord compression who have recurrent metastatic tumors at previously operated spinal levels. In carefully selected patients, reoperation can prolong ambulation and result in good functional and neurological outcomes.

Entities:  

Mesh:

Year:  2010        PMID: 20594025     DOI: 10.3171/2010.3.SPINE08670

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  7 in total

1.  Predictors of quality of life improvement after surgery for metastatic tumors of the spine: prospective cohort study.

Authors:  Ori Barzilai; Lily McLaughlin; Mary-Kate Amato; Anne S Reiner; Shahiba Q Ogilvie; Eric Lis; Yoshiya Yamada; Mark H Bilsky; Ilya Laufer
Journal:  Spine J       Date:  2017-11-06       Impact factor: 4.166

2.  Surgical Decompression of High-Grade Spinal Cord Compression from Hormone Refractory Metastatic Prostate Cancer.

Authors:  Muhammad Omar Chohan; Sweena Kahn; Gustav Cederquist; Anne S Reiner; Joseph Schwab; Ilya Laufer; Mark Bilsky
Journal:  Neurosurgery       Date:  2018-05-01       Impact factor: 4.654

Review 3.  Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement.

Authors:  Thomas Breakell; Heidi Waibel; Stefan Schliep; Barbara Ferstl; Michael Erdmann; Carola Berking; Markus V Heppt
Journal:  Curr Oncol       Date:  2022-04-19       Impact factor: 3.109

Review 4.  Evaluating ambulatory function as an outcome following treatment for spinal metastases: a systematic review.

Authors:  Lananh Nguyen; Nicole Agaronnik; Marco L Ferrone; Jeffrey N Katz; Andrew J Schoenfeld
Journal:  Spine J       Date:  2021-05-13       Impact factor: 4.297

5.  Radical surgery consisting of en bloc corpectomy in recurrence after palliative surgery for spinal metastasis.

Authors:  Shurei Sugita; Hideki Murakami; Noritaka Yonezawa; Satoru Demura; Sakae Tanaka; Hiroyuki Tsuchiya
Journal:  Spine Surg Relat Res       Date:  2017-12-20

6.  Radiographic Rate and Clinical Impact of Pseudarthrosis in Spine Radiosurgery for Metastatic Spinal Disease.

Authors:  Michael Zhang; Geoff Appelboom; John K Ratliff; Scott G Soltys; John R Adler; Jon Park; Steven D Chang
Journal:  Cureus       Date:  2018-11-25

7.  Survival Outcomes and Factors Associated with Revision Surgery for Metastatic Disease of the Spine.

Authors:  Vignesh K Alamanda; Myra M Robinson; Jeffrey S Kneisl; Leo R Spector; Joshua C Patt
Journal:  J Oncol       Date:  2018-06-25       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.